<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800722</url>
  </required_header>
  <id_info>
    <org_study_id>NIH/LAMMP6383</org_study_id>
    <nct_id>NCT00800722</nct_id>
  </id_info>
  <brief_title>A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.</brief_title>
  <official_title>Phase I Combined Use of Pulsed Dye Laser and Rapamycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beckman Laser Institute University of California Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to improve port wine stain therapeutic outcome in response to
      laser therapy. The researchers want to determine whether the combined use of pulsed dye laser
      therapy and rapamycin will improve PWS therapeutic outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researchers want to combined use of pulsed dye laser to induce port wine stain blood
      vessel injury, and rapamycin directly inhibits the proliferation of vascular endothelial
      cells driven by vascular endothelial growth factor which preventing port wine stain
      angiogenesis and recanalization, to improve port wine stain lesion blanching.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improve port wine stain (PWS) therapeutic outcome</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Port Wine Stain</condition>
  <arm_group>
    <arm_group_label>Treatment of Port Wine Stain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin Treatment of Port Wine Stain</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin Treatment of Port Wine Stain</intervention_name>
    <description>Treatment of Port Wine Stain</description>
    <arm_group_label>Treatment of Port Wine Stain</arm_group_label>
    <other_name>Treatment of Port Wine Stain</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  port wine stain birthmarks suitable for comparison testing.

        Exclusion Criteria:

          -  Pregnancy.

          -  Abnormal blood hematology or chemistry blood tests or urine analysis.

          -  History of cancer, History of high cholesterol, lipids or liver disease

          -  Allergy to macrolide drugs (e.g., erythromycin).

          -  Any therapy within the previous two months to the proposed PWS treatment sites.

          -  Concurrent use of known photosensitizing drugs,immunosuppressive drugs or systemic
             steroids,antifungals, antiepileptics, HIV protease inhibitors, cimetidine, cisapride,
             clarithromycin, dannzol, diltiazem, erythromycin, metoclopramide, rifabutin, rifampin,
             rifapentine, troleandomycin, or verapamil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John S Nelson, M.D,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beckman Laser Institute University of California Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beckman Laser Institute Medical clinic</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Beckman Laser Institute and Medical Center</investigator_full_name>
    <investigator_title>J S Nelson, M.D., Ph.D.,Professor of Surgery and Biomedical Engineering</investigator_title>
  </responsible_party>
  <keyword>hypervascular anomalies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Port-Wine Stain</mesh_term>
    <mesh_term>Hemangioma, Capillary</mesh_term>
    <mesh_term>Vascular Malformations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

